Form 4: Compass Therapeutics CFO Granted Equity Awards

Compass Therapeutics' CFO, Barry Shin, was granted 125,000 restricted stock units and 670,000 stock options on January 2, 2026.

Summary

• CFO Barry Shin of Compass Therapeutics, Inc. (CMPX) was granted equity awards on January 2, 2026.
• The grants include 125,000 restricted stock units (RSUs) at a price of $5.17 per share.
• These RSUs are subject to service-based vesting conditions and will vest in four equal annual installments, with the first vesting on January 2, 2027.
• Additionally, 670,000 stock options were granted with an exercise price of $5.17 per share.
• These stock options will vest over 48 substantially equal monthly installments, commencing on February 2, 2026, and have an expiration date of January 2, 2036.
• Following these transactions, Barry Shin beneficially owns 525,000 shares of common stock (including unvested RSUs) and 670,000 derivative stock options.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive like the CFO is generally viewed positively as it aligns management's long-term interests with those of shareholders, incentivizing performance and retention.

Positives

• Grant of 125,000 restricted stock units (RSUs) to CFO Barry Shin, aligning management interests with long-term shareholder value.
• Grant of 670,000 stock options to CFO Barry Shin, providing a significant long-term incentive and linking executive compensation directly to company performance.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend through January 2, 2027, for RSUs and January 2, 2036, for stock options, indicating a long-term incentive structure for the CFO.

Industry Context

This Form 4 filing reflects a standard practice of public companies to use equity grants, such as restricted stock units and stock options, as a key component of executive compensation packages. These grants are designed to align the interests of company leadership with long-term shareholder value creation, a common strategy across the biotechnology and pharmaceutical sectors where long development cycles necessitate long-term incentives.

Stakeholder Impact

• Shareholders: Potential for increased alignment between management and shareholder interests; minor potential dilution from future share issuance upon vesting/exercise.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• Vesting of 125,000 restricted stock units in four equal annual installments, starting January 2, 2027.
• Vesting of 670,000 stock options over 48 substantially equal monthly installments, starting February 2, 2026.

Key Dates

Keywords

Compass Therapeutics, CMPX, Barry Shin, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation